Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Kalaris Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 60 | 1 | 53 | −6 |
| Shares | 44.9M | 60.5K | 49.6M | +4.78M (+10.7%) |
| Value | $36.3M | $48.9K | $20.7M | −$15.6M (−43.0%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gilead Sciences, Inc. | 16,635,286 | $6.99M | 0.45% |
| Jacobs Levy Equity Management, Inc | 664,423 | $279.1K | 0.00% |
| Tang Capital Management LLC | 552,264 | $232.0K | 0.02% |
| Woodline Partners LP | 451,858 | $189.8K | 0.00% |
| Squarepoint Ops LLC | 337,943 | $141.9K | 0.00% |
| BNP Paribas Arbitrage, SA | 74,963 | $31.5K | 0.00% |
| Raymond James Financial Inc | 60,500 | $25.4K | 0.00% |
| Virtu Financial LLC | 46,576 | $20.0K | 0.00% |
| Two Sigma Securities, LLC | 32,579 | $13.7K | 0.00% |
| HRT Financial LP | 31,586 | $13.0K | 0.00% |
| SBI Securities Co., Ltd. | 18 | $8 | 0.00% |
Sold out (17)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Acuitas Investments, LLC | 1,069,696 | $864.8K |
| D. E. Shaw & Co., Inc. | 296,461 | $239.7K |
| Acadian Asset Management LLC | 224,343 | $181.0K |
| Commonwealth Equity Services, LLC | 201,000 | $163.0K |
| Marquette Asset Management, LLC | 178,883 | $144.6K |
| Price T Rowe Associates Inc | 85,900 | $70.0K |
| Charles Schwab Investment Management Inc | 57,055 | $46.1K |
| Amundi | 45,448 | $36.0K |
| XTX Topco Ltd | 26,523 | $21.4K |
| AQR Capital Management LLC | 20,843 | $16.9K |
| Cubist Systematic Strategies, LLC | 19,997 | $16.2K |
| JustInvest LLC | 14,331 | $11.6K |
| Point72 (DIFC) Ltd | 14,200 | $11.5K |
| Catalyst Funds Management Pty Ltd | 13,000 | $10.5K |
| Strengthening Families & Communities, LLC | 6,200 | $5.01K |
| SRS Capital Advisors, Inc. | 451 | $365 |
| Nisa Investment Advisors, LLC | 8 | $6 |
Not filed for Q4 2024 yet (1)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 60,500 | $48.9K |